Bli medlem
Bli medlem

Du är här

2020-10-21

Managers’ transactions

October 21, 2020
Announcement no. 20

Managers’ transactions

In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 19, BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons with managerial responsibilities in BioPorto A/S and/or persons closely related with them.

1. Details of the person discharging managerial responsibilities/person closely associated
a) NameChristopher James Lindop
2. Reason for the notification 
a) Position/statusMember of the Board of Directors of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type

of instrument



Identification code
Shares

 


ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020
b) Nature of the transactionPurchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)Price: DKK 1.6, Volume: 111,621
d) Aggregated information
  • Aggregated volume
  • Aggregated price
N/A
e) Date of the transaction2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)
f) Place of the transactionNasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated
a) NameOle Larsen
2. Reason for the notification 
a) Position/statusChief Financial Officer of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type

of instrument



Identification code
Shares

 


ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020
b) Nature of the transactionPurchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)Price: DKK 1.6, Volume: 108,468
d) Aggregated information
  • Aggregated volume
  • Aggregated price
N/A
e) Date of the transaction2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)
f) Place of the transactionNasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated
a) NameTherazone ApS
2. Reason for the notification 
a) Position/statusClosely associated person to Thomas Magnussen, Chairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type

of instrument



Identification code
Shares

 


ISIN code DK0061409042 to be merged with permanent ISIN code DKDK0011048619, expectedly no later than on 21 October 2020
b) Nature of the transactionPurchase (exercise of subscription rights in connection with rights issue)
c) Price(s) and volume(s)Price: DKK 1.6, Volume: 311,220
d) Aggregated information
  • Aggregated volume
  • Aggregated price
N/A
e) Date of the transaction2020-10-21 8.30 a.m. UTC (10:30 a.m. CEST)
f) Place of the transactionNasdaq Copenhagen A/S, XCSE

For further information, please contact:

Peter Mørch Eriksen, CEO
Ole Larsen, CFO
Telephone +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

Författare BioPorto A/S

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.